258 related articles for article (PubMed ID: 28356022)
1. Synthesis and Evaluation of Some Dibromoquinazoline-sulphonamide Hybrids and some Schiff´s Base Analogs for their Cytotoxic Activity.
Ahmed MF; El-Haggar R
Anticancer Agents Med Chem; 2017 Nov; 17(11):1563-1569. PubMed ID: 28356022
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
Ahmed MF; Magdy N
Anticancer Agents Med Chem; 2017; 17(6):832-838. PubMed ID: 27671305
[TBL] [Abstract][Full Text] [Related]
3. Quinazoline-sulfonamides as potential antitumor agents: synthesis and biological testing.
Alafeefy AM; Alqasoumi SI; Ashour AE; Alshebly MM
J Enzyme Inhib Med Chem; 2013 Apr; 28(2):375-83. PubMed ID: 22468752
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis.
El-Azab AS; Abdel-Aziz AA; AlSaif NA; Alkahtani HM; Alanazi MM; Obaidullah AJ; Eskandrani RO; Alharbi A
Bioorg Chem; 2020 Nov; 104():104345. PubMed ID: 33142413
[TBL] [Abstract][Full Text] [Related]
5. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents.
Poudapally S; Battu S; Velatooru LR; Bethu MS; Janapala VR; Sharma S; Sen S; Pottabathini N; Iska VBR; Katangoor V
Bioorg Med Chem Lett; 2017 May; 27(9):1923-1928. PubMed ID: 28351589
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
Ahmed MF; Belal A
Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors.
Abdelgawad MA; Bakr RB; Alkhoja OA; Mohamed WR
Bioorg Chem; 2016 Jun; 66():88-96. PubMed ID: 27043178
[TBL] [Abstract][Full Text] [Related]
11. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
12. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anticancer activity of some novel trifluoromethylquinolines carrying a biologically active benzenesulfonamide moiety.
Al-Dosari MS; Ghorab MM; Alsaid MS; Nissan YM; Ahmed AB
Eur J Med Chem; 2013 Nov; 69():373-83. PubMed ID: 24077528
[TBL] [Abstract][Full Text] [Related]
15. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents.
Alafeefy AM; Ashour AE
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):541-5. PubMed ID: 21851213
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and Antibacterial Evaluation of O-Alkylated/Acylated Quinazolin-4-one Schiff Bases.
Manhas N; Singh P; Mocktar C; Singh M; Koorbanally N
Chem Biodivers; 2021 May; 18(5):e2100096. PubMed ID: 33724670
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
20. Anticancer and radiosensitizing evaluation of some new pyranothiazole-Schiff bases bearing the biologically active sulfonamide moiety.
Ghorab MM; Shaaban MA; Refaat HM; Heiba HI; Ibrahim SS
Eur J Med Chem; 2012 Jul; 53():403-7. PubMed ID: 22583778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
